Diagonal Bio receives order from the Technical University of Denmark
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has secured an order from the Technical University of Denmark (“DTU”) valued at just over 210,000 SEK for fish farms’ health project HURTIGFISK. The order includes supply of Diagonal Bios diagnostic instrument LAMPlify®, consumables and consulting services. The project aims to revolutionise monitoring of fish farm diseases, by point-of-care diagnostics.
The Technical University of Denmark (DTU) and Copenhagen University (KU) has received funding for a fish health project, HURTIGFISK, a project which is a part of KU's efforts to advance fish diagnostics. Diagonal Bio will be a subcontractor to the project as the order includes delivery of the LAMPlify® instrument, along with consumables and comprehensive consulting services. The HURTIGFISK project is scheduled to begin on November 1st and the revenues from the received order will partly be recognised starting from the fourth quarter.
The HURTIGFISK project aims to develop assays against fish pathogens that can drastically reduce the incidence of diseases in fish farming through rapid and accurate testing and diagnosis. By utilising the technology eLAMP embedded in LAMPlify®, fish producers will explore the possibility to conduct disease diagnoses in fishes within 15 minutes. This capability is expected to reduce the number of disease-related fish deaths by 50%, significantly enhancing both animal welfare and productivity.
"By incorporating eLAMP technology into our HURTIGFISK project, we can develop new assays and hopefully achieve a level of precision, speed and diagnosis that has not been possible before. This will make a substantial difference to both animal welfare and productivity within the fish industry" - Helene Larsen, Head of Centre for Diagnostics at DTU Health Tech
"DTU has been a valued partner of Diagonal Bio since the early stages, and collaborating with them on a project of this scale and significance proves the trust and strength of our partnership. We are extremely proud to be a subcontractor to the project HURTIGFISK and look forward to contributing with our expertise and technology." - Karin Wehlin, CEO of Diagonal Bio
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on August 21, 2024, at 15:10 CET.
For additional information about Diagonal Bio AB
Please contact: Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.